LANTERN PHARMA INC (LTRN) Fundamental Analysis & Valuation

NASDAQ:LTRN • US51654W1018

2.73 USD
-0.03 (-1.09%)
Last: Mar 11, 2026, 10:54 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This LTRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

LTRN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. The financial health of LTRN is average, but there are quite some concerns on its profitability. LTRN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. LTRN Profitability Analysis

1.1 Basic Checks

  • In the past year LTRN has reported negative net income.
  • LTRN had a negative operating cash flow in the past year.
  • LTRN had negative earnings in each of the past 5 years.
  • In the past 5 years LTRN always reported negative operating cash flow.
LTRN Yearly Net Income VS EBIT VS OCF VS FCFLTRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • LTRN has a worse Return On Assets (-138.85%) than 82.85% of its industry peers.
  • LTRN has a worse Return On Equity (-197.36%) than 67.44% of its industry peers.
Industry RankSector Rank
ROA -138.85%
ROE -197.36%
ROIC N/A
ROA(3y)-47.36%
ROA(5y)-37.56%
ROE(3y)-54.18%
ROE(5y)-41.96%
ROIC(3y)N/A
ROIC(5y)N/A
LTRN Yearly ROA, ROE, ROICLTRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

  • LTRN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LTRN Yearly Profit, Operating, Gross MarginsLTRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LTRN Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for LTRN has been increased compared to 1 year ago.
  • LTRN has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for LTRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LTRN Yearly Shares OutstandingLTRN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
LTRN Yearly Total Debt VS Total AssetsLTRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • LTRN has an Altman-Z score of -8.50. This is a bad value and indicates that LTRN is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of LTRN (-8.50) is worse than 70.71% of its industry peers.
  • There is no outstanding debt for LTRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.5
ROIC/WACCN/A
WACCN/A
LTRN Yearly LT Debt VS Equity VS FCFLTRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • LTRN has a Current Ratio of 3.33. This indicates that LTRN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of LTRN (3.33) is worse than 60.50% of its industry peers.
  • A Quick Ratio of 3.33 indicates that LTRN has no problem at all paying its short term obligations.
  • LTRN has a Quick ratio of 3.33. This is comparable to the rest of the industry: LTRN outperforms 41.43% of its industry peers.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 3.33
LTRN Yearly Current Assets VS Current LiabilitesLTRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. LTRN Growth Analysis

3.1 Past

  • LTRN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.69%.
EPS 1Y (TTM)1.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • LTRN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.06% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.74%
EPS Next 2Y-0.47%
EPS Next 3Y-2.2%
EPS Next 5Y-3.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LTRN Yearly Revenue VS EstimatesLTRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 20M 40M 60M
LTRN Yearly EPS VS EstimatesLTRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. LTRN Valuation Analysis

4.1 Price/Earnings Ratio

  • LTRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LTRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LTRN Price Earnings VS Forward Price EarningsLTRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LTRN Per share dataLTRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • LTRN's earnings are expected to decrease with -2.20% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.47%
EPS Next 3Y-2.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LTRN Dividend Analysis

5.1 Amount

  • LTRN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LTRN Fundamentals: All Metrics, Ratios and Statistics

LANTERN PHARMA INC

NASDAQ:LTRN (3/11/2026, 10:54:00 AM)

2.73

-0.03 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-13
Inst Owners19.96%
Inst Owner Change-0.26%
Ins Owners0.41%
Ins Owner Change0%
Market Cap30.52M
Revenue(TTM)N/A
Net Income(TTM)-18.92M
Analysts82.86
Price Target20.4 (647.25%)
Short Float %3.19%
Short Ratio5.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.9%
Min EPS beat(2)18.65%
Max EPS beat(2)19.14%
EPS beat(4)3
Avg EPS beat(4)12.49%
Min EPS beat(4)-3.81%
Max EPS beat(4)19.14%
EPS beat(8)6
Avg EPS beat(8)10.32%
EPS beat(12)10
Avg EPS beat(12)15.19%
EPS beat(16)13
Avg EPS beat(16)15.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.18
P/tB 3.18
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-1.51
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -138.85%
ROE -197.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.36%
ROA(5y)-37.56%
ROE(3y)-54.18%
ROE(5y)-41.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.33
Quick Ratio 3.33
Altman-Z -8.5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)166.97%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.14%
EPS Next Y11.74%
EPS Next 2Y-0.47%
EPS Next 3Y-2.2%
EPS Next 5Y-3.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-96.32%
EBIT Next 3Y-41.56%
EBIT Next 5Y-25.19%
FCF growth 1Y-23.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.67%
OCF growth 3YN/A
OCF growth 5YN/A

LANTERN PHARMA INC / LTRN FAQ

Can you provide the ChartMill fundamental rating for LANTERN PHARMA INC?

ChartMill assigns a fundamental rating of 2 / 10 to LTRN.


What is the valuation status for LTRN stock?

ChartMill assigns a valuation rating of 0 / 10 to LANTERN PHARMA INC (LTRN). This can be considered as Overvalued.


How profitable is LANTERN PHARMA INC (LTRN) stock?

LANTERN PHARMA INC (LTRN) has a profitability rating of 0 / 10.


What is the financial health of LANTERN PHARMA INC (LTRN) stock?

The financial health rating of LANTERN PHARMA INC (LTRN) is 6 / 10.